Optima Research-Boardman

Boardman, Ohio 44512

3 studies enrolling now · 12 studies all time

What they study most

Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Hand and Foot Dermatitis, Chronic Spontaneous Urticaria, Common Warts, Common Warts (Verruca Vulgaris), Hidradenitis Suppurativa, Hidradenitis Suppurativa (HS), Human Papilloma Virus (HPV), Moderate Psoriasis, Obesity, Overweight or Obesity

Studies at this site

• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Recruiting now
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) — Recruiting now
• A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Running, not enrolling
• Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) — Completed
• A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis — Running, not enrolling
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 — Completed
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis — Stopped early
• Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis — Completed